Sagimet Biosciences Inc - Class A
Research Sagimet Biosciences Inc - Class A (SGMT) on Bullrun: market cap USD 543.69M. Explore financials, valuation history, model signals, and stock context.
Key Metrics
- TickerSGMT
- ExchangeNASDAQ
- CountryUnited States
- SectorHealthcare
- IndustryBiotechnology
- CurrencyUSD
- Market capUSD 543.69M
- Financial periodQ2 2026
- RevenueUSD 0
- Net income-USD 13.95M
- Free cash flow-USD 11.10M
Valuation Snapshot
latest market cap is USD 543.69M.
Five-year financial history
| Year | Revenue | Net income | Free cash flow | Gross margin | Diluted EPS | Cash | Total debt | Equity |
|---|---|---|---|---|---|---|---|---|
| FY2025 | USD 0 | -USD 51.04M | -USD 45.65M | n/a | -1.58 | USD 35.02M | USD 78.00K | USD 111.38M |
| FY2024 | USD 0 | -USD 45.57M | -USD 42.44M | n/a | -1.45 | USD 75.84M | USD 78.00K | USD 155.81M |
| FY2023 | USD 2.00M | -USD 27.88M | -USD 23.77M | n/a | -2.66 | USD 75.14M | USD 65.00K | USD 91.07M |
| FY2022 | USD 0 | -USD 30.50M | -USD 24.49M | n/a | -165.2 | USD 158.00K | USD 211.00K | -USD 186.95M |
Valuation history
| Year | Snapshot date | Market cap | P/E | Dividend yield | Annual dividend/share |
|---|---|---|---|---|---|
| 2026 | 2026-10-12 | USD 543.69M | n/a | n/a | n/a |
| 2025 | 2025-12-31 | USD 190.60M | n/a | n/a | n/a |
| 2024 | 2024-12-31 | USD 144.88M | n/a | n/a | n/a |
| 2023 | 2023-12-29 | USD 124.10M | n/a | n/a | n/a |
About Sagimet Biosciences Inc - Class A
Sagimet Biosciences Inc., a clinical-stage biopharmaceutical company, develops novel therapeutics called fatty acid synthase (FASN) inhibitors for the treatment of diseases that result from dysfunctional metabolic and fibrotic pathways in the United States. The company's lead drug candidate is Denifanstat, an oral, once-daily pill and selective FASN inhibitor for the treatment of metabolic dysfunction-associated steatohepatitis, acne, and select forms of cancer.
Related stock research
Other Healthcare stocks
Frequently asked questions
What is Sagimet Biosciences Inc - Class A's market cap?
Sagimet Biosciences Inc - Class A's market capitalization is USD 543.69M.
What does Sagimet Biosciences Inc - Class A do?
Sagimet Biosciences Inc., a clinical-stage biopharmaceutical company, develops novel therapeutics called fatty acid synthase (FASN) inhibitors for the treatment of diseases that result from dysfunctional metabolic and fibrotic pathways in the United States. The company's lead drug candidate is Denifanstat, an oral, once-daily pill and selective FASN inhibitor for the treatment of metabolic dysfunction-associated steatohepatitis, acne, and select forms of cancer.